BioMarin Buys Rare Disease-Focused Amicus In $4.8 Billion Deal
BioMarin Pharmaceutical (BMRN) said Friday it will acquire Amicus Therapeutics (FOLD) for $4.8 billion in a deal that adds two ...
Monday, September 14, 2026
Tag: Amicus
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.